

## Contents

<i>List of Contributors</i>	<i>page</i> xi
<i>Acknowledgments</i>	xv
<b>Introduction</b>	
Carmel Shachar, I. Glenn Cohen, Holly Fernandez Lynch, and Barbara J. Evans	1
<b>PART I: TRANSPARENCY IN HEALTH AND HEALTH CARE: THEMATIC ISSUES</b>	13
<b>Introduction to Part I</b>	15
Abigail R. Moncrieff	
<b>1 Smashing into Windows: The Limits of Consumer Sovereignty in Health Care</b>	17
Barry R. Furrow	
<b>2 The Interplay of Privacy and Transparency in Health Care: The HIPAA Privacy Rule as a Case Study</b>	30
Barbara J. Evans	
<b>3 Transparency Trade-offs: Priority Setting, Scarcity, and Health Fairness</b>	44
Govind Persad	
<b>4 Slightly Hazy: Transparency and the Costs of Too Much Information</b>	58
Oliver J. Kim	

	<b>PART II: TRANSPARENCY AND INFORMED CONSENT</b>	69
	<b>Introduction to Part II</b>	71
	Luke Gelas	
5	<b>Transparency versus Informed Consent: The Patient/Consumer Paradigms</b>	75
	Craig J. Konnoth	
6	<b>Transparency and Financial Conflicts: The Uncertain Case for Sunshine</b>	88
	Richard S. Saver	
7	<b>Making Religion Transparent: The Substance, Process, and Efficacy of Disclosing Religious Restrictions on Care</b>	103
	Elizabeth Sepper	
	<b>PART III: TRANSPARENCY AND ECONOMICS: HEALTH CARE COSTS AND BILLING</b>	115
	<b>Introduction to Part III</b>	117
	Kristin M. Madison	
8	<b>Transparency on Prescription Drug Research Expenditures: A Lever for Restraining Pricing?</b>	121
	Ameet Sarpatwari, Jerry Avorn, and Aaron S. Kesselheim	
9	<b>Is Pharmaceutical Price Transparency an Effective Means to Reduce High Prices and Wide Variations?</b>	132
	Marc A. Rodwin	
10	<b>Price Transparency: A Contracts Solution</b>	153
	Wendy Netter Epstein	
11	<b>Solving Surprise Medical Bills</b>	165
	Mark A. Hall	
	<b>PART IV: TRANSPARENCY AND INNOVATION</b>	179
	<b>Introduction to Part IV</b>	181
	Holly Fernandez Lynch	
12	<b>Increasing the Transparency of FDA Review to Enhance the Innovation Process</b>	185
	Rachel E. Sachs and Thomas J. Hwang	

<i>Contents</i>		ix
13	<b>Transparency and Clinical Trial Data Sharing: Legal and Policy Issues</b> Barbara E. Bierer, Mark Barnes, and Rebecca Li	196
14	<b>The European Medicines Agency's Approach to Transparency</b> Stefano Marino and Spyridon Drosos	210
	<b>PART V: TRANSPARENCY AND OUTCOMES: PROMOTING HEALTH AND SAFETY</b>	227
	<b>Introduction to Part V</b> Gregory Curfman	229
15	<b>The Role of Transparency in Promoting Healthy Behaviors: Pros, Cons, and Perils of Information Sharing to Foster Personal Responsibility in Health Care</b> Anthony W. Orlando and Arnold J. Rosoff	233
16	<b>The Role of Transparency in Patient Safety Improvement</b> Michelle M. Mello, David M. Studdert, Brahmajee K. Nallamothu, and Allen Kachalia	244
17	<b>Personal Health Records as a Tool for Transparency in Health Care</b> Sharona Hoffman	260
18	<b>Nontransparency in Electronic Health Record Systems</b> Jim Hawkins, Barbara J. Evans, and Harlan M. Krumholz	273
19	<b>Transparency Challenges in Reproductive Health Care</b> Dov Fox	286
	<b>PART VI: CHALLENGES IN PROMOTING AND MEASURING TRANSPARENCY IN HEALTH CARE</b>	297
	<b>Introduction to Part VI</b> I. Glenn Cohen	299
20	<b>ERISA as a Barrier for State Health Care Transparency Efforts</b> Erin C. Fuse Brown and Jaime S. King	301
21	<b>Transparency and Data Sharing in Clinical Research and Big Pharma</b> Jennifer E. Miller	314

- |    |   |     |
|----|---|-----|
| 22 | <b>Promoting IRB Transparency: About What, To Whom, Why, and How?</b>   | 329 |
|    | Holly Fernandez Lynch   |     |
| 23 | <b>Using Disclosure to Regulate PBMs: The Dark Side of Transparency</b> | 343 |
|    | David A. Hyman and William E. Kovacic                                   |     |